CA2676387A1 - Combination therapy - Google Patents

Combination therapy Download PDF

Info

Publication number
CA2676387A1
CA2676387A1 CA002676387A CA2676387A CA2676387A1 CA 2676387 A1 CA2676387 A1 CA 2676387A1 CA 002676387 A CA002676387 A CA 002676387A CA 2676387 A CA2676387 A CA 2676387A CA 2676387 A1 CA2676387 A1 CA 2676387A1
Authority
CA
Canada
Prior art keywords
romidepsin
bortezomib
approximately
cancer
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002676387A
Other languages
English (en)
French (fr)
Inventor
Mitchell Keegan
Steven Grant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Gloucester Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2676387A1 publication Critical patent/CA2676387A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002676387A 2007-01-23 2008-01-23 Combination therapy Abandoned CA2676387A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88616907P 2007-01-23 2007-01-23
US60/886,169 2007-01-23
US577407P 2007-12-07 2007-12-07
US61/005,774 2007-12-07
PCT/US2008/000850 WO2008091620A2 (en) 2007-01-23 2008-01-23 Combination therapy comprising romidepsin and i.a. bortezomib

Publications (1)

Publication Number Publication Date
CA2676387A1 true CA2676387A1 (en) 2008-07-31

Family

ID=39323892

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002676387A Abandoned CA2676387A1 (en) 2007-01-23 2008-01-23 Combination therapy

Country Status (8)

Country Link
US (1) US20090105200A1 (https=)
EP (1) EP2117556A2 (https=)
JP (1) JP2010516767A (https=)
AU (1) AU2008209555A1 (https=)
CA (1) CA2676387A1 (https=)
IL (1) IL199992A0 (https=)
MX (1) MX2009007777A (https=)
WO (1) WO2008091620A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY171061A (en) 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
AU2007342028B2 (en) * 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
CN101687010A (zh) * 2006-12-29 2010-03-31 格洛斯特制药公司 制备Romidepsin
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
KR20160091440A (ko) * 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
WO2010106135A1 (en) 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combined use for the treatment of ovarian carcinoma
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
CA2763471A1 (en) * 2009-05-27 2010-12-02 Cephalon, Inc. Combination therapy for the treatment of multiple myeloma
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CN102946879B (zh) * 2010-04-19 2015-04-22 尼基制药公司 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
EP3352793A1 (en) * 2015-09-21 2018-08-01 IFOM Fondazione Istituto Firc di Oncologia Molecolare New therapeutic strategies against blood cancer
EP3380086B1 (en) 2015-11-25 2021-10-13 IO Therapeutics, Inc. Cyp26-resistant rar-alpha selective agonists in the treatment of cancer
CN119698276A (zh) * 2022-06-07 2025-03-25 蓝腾制药公司 用酰基富烯与依鲁替尼或硼替佐米的组合治疗癌症

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2238982T1 (sl) * 2003-06-27 2013-01-31 Astellas Pharma Inc. Terapevtsko sredstvo za mehkotkivni sarkom
JP2009539862A (ja) * 2006-06-09 2009-11-19 メリオン リサーチ Ｉｉｉ リミテッド 強化剤を含む固体経口投与剤形
AU2007296259A1 (en) * 2006-09-15 2008-03-20 Janssen Pharmaceutica Nv Combinations of class-I specific histone deacetylase inhibitors with proteasome inhibitors
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors

Also Published As

Publication number Publication date
US20090105200A1 (en) 2009-04-23
WO2008091620A3 (en) 2008-09-18
IL199992A0 (en) 2010-04-15
JP2010516767A (ja) 2010-05-20
WO2008091620A2 (en) 2008-07-31
EP2117556A2 (en) 2009-11-18
MX2009007777A (es) 2009-12-16
AU2008209555A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
US20090105200A1 (en) Combination therapy
Smolewski et al. The discovery and development of romidepsin for the treatment of T-cell lymphoma
RU2481853C2 (ru) Улучшенные способы лечения опухолей
US20100093610A1 (en) Romidepsin-based treatments for cancer
WO2007145704A2 (en) Gemcitabine combination therapy
US5736536A (en) Method for treating vascular leak syndrome
EP2263694A1 (en) Antitumor agent comprising the histone deacetylase inhibitor FK228 and a topoisomerase II inhibitor
WO2008127659A2 (en) Combination therapy for cancer
EP1492596A1 (en) Depsipeptide for therapy of kidney cancer
NZ541634A (en) Improved antitumoral treatments
US9795650B2 (en) Romidepsin formulations and uses thereof
US20110015168A1 (en) Methods for increasing levels of human fetal hemoglobin
US20190192559A1 (en) Combination of proteasome inhibitors and anti-cd30 antibodies
Cheson New Developmental Agents and Directions in the Treatment of Acute Myelogenous Leukemia
CHESON of Acute Myelogenous Leukemia
Tosi et al. Novel proteasome inhibitors
HK1168047A (en) Romidepsin-based treatments for cancer

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130123